HK Stock Market Move | English Silicon Intelligence (03696) surged over 11% on the day after its initial public offering, rising nearly 40% compared to the offering price. Its total market value surpassed HK$18 billion.

On the second day of its listing, Insilico Medicine (03696) rose by more than 11%, reaching 33.62 Hong Kong dollars, nearly 40% higher than the offer price of 24.05 Hong Kong dollars. As of the time of publication, it rose by 11.14%, to 33.32 Hong Kong dollars, with a turnover of 83.8921 million Hong Kong dollars and a total market value exceeding 18 billion Hong Kong dollars. Public information shows that Insilico Medicine was established in 2014 and is a leading enterprise in the field of AI-driven drug discovery and development in China. As of December 10, 2025, the company has generated over 20 clinical or IND-stage assets through its self-developed generative artificial intelligence platform Pharma.AI, three of which have been licensed to international pharmaceutical companies for a total contract value of up to $2.1 billion, and one Phase II asset in the self-development stage at a relatively advanced stage in the industry. In addition, according to Frost & Sullivan, the AI Drug Discovery and Development (AIDD) market is expected to grow from $11.9 billion in 2023 to $74.6 billion in 2032, with a compound annual growth rate (CAGR) of 22.6%.